OmniAb, Inc. (NASDAQ:OABI) Shares Sold by Jane Street Group LLC

Jane Street Group LLC lessened its holdings in OmniAb, Inc. (NASDAQ:OABI) by 21.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 136,359 shares of the company’s stock after selling 36,694 shares during the quarter. Jane Street Group LLC owned about 0.12% of OmniAb worth $577,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of OABI. Isthmus Partners LLC increased its holdings in OmniAb by 37.2% in the 2nd quarter. Isthmus Partners LLC now owns 528,385 shares of the company’s stock worth $1,981,000 after buying an additional 143,387 shares during the period. American Century Companies Inc. increased its holdings in OmniAb by 52.7% in the 2nd quarter. American Century Companies Inc. now owns 110,036 shares of the company’s stock worth $413,000 after buying an additional 37,963 shares during the period. Dimensional Fund Advisors LP increased its holdings in OmniAb by 6.9% in the 2nd quarter. Dimensional Fund Advisors LP now owns 3,012,216 shares of the company’s stock worth $11,296,000 after buying an additional 194,835 shares during the period. Sei Investments Co. grew its stake in shares of OmniAb by 11.0% during the 2nd quarter. Sei Investments Co. now owns 29,024 shares of the company’s stock worth $109,000 after purchasing an additional 2,888 shares during the period. Finally, Squarepoint Ops LLC acquired a new stake in shares of OmniAb during the 2nd quarter worth approximately $449,000. Institutional investors and hedge funds own 72.08% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the stock. Benchmark reaffirmed a “buy” rating and set a $8.00 price objective on shares of OmniAb in a research note on Thursday, November 14th. HC Wainwright reaffirmed a “buy” rating and set a $11.00 price objective on shares of OmniAb in a research note on Thursday, November 14th.

OmniAb Price Performance

Shares of NASDAQ:OABI opened at $3.68 on Friday. OmniAb, Inc. has a 1 year low of $3.43 and a 1 year high of $6.72. The firm has a market capitalization of $519.67 million, a price-to-earnings ratio of -5.94 and a beta of -0.10. The business’s 50 day moving average price is $3.92 and its 200-day moving average price is $4.11.

About OmniAb

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.